MEPRIAM Drug Patent Profile
✉ Email this page to a colleague
When do Mepriam patents expire, and when can generic versions of Mepriam launch?
Mepriam is a drug marketed by Teva and is included in one NDA.
The generic ingredient in MEPRIAM is meprobamate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the meprobamate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mepriam
A generic version of MEPRIAM was approved as meprobamate by INVAGEN PHARMS on February 27th, 2008.
Summary for MEPRIAM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 41 |
Patent Applications: | 4,658 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MEPRIAM at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MEPRIAM
US Patents and Regulatory Information for MEPRIAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | MEPRIAM | meprobamate | TABLET;ORAL | 016069-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |